10554036 - GAU: 1626

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 12 4

Col	mplete if Known	
Application Number	10/554,036	
Filing Date	October 20, 2005	
First Named Inventor	Besidski	
Art Unit	Unknow.	
Examiner Name	Unknown STOCKTON	_
Attorney Docket Number	101023-1P US	

			U. S. PATEN	T DOCUMENTS	· · · · · · · · · · · · · · · · · · ·
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	^{US-} 3,506,767	04-14-1970	Frick et al.	
	A2	^{US-} 3,711,608	01-16-1973	Campbell	
	А3	^{US-} 5,482,956	01-09-1996	Lunkenheimer et al.	
		US-			-
		US-			
	_	US-			
		US-			
		US-			
		US-			

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
	A4	EP 0599382	06-01-1994	Eastman Kodak Company		
	A5	EP 0599384	06-01-1994	Eastman Kodak Company		
	A6	WO 94/14801	07-07-1994	Smithkline Beecham PLC		
	A7	WO 01/12188	02-22-2001	Pharmacia & Upjohn et al.		
	A8	WO 02/090326	11-14-2002	Smithkline Beecham PLC		
	A9	WO 02/42273	05-30-2002	Bristol-Myers Squibb Co.		

Examiner Signature	/Laura L. Stockton/	Date Considered	12/04/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Receipt date: 03/17/2006

10554036 - GAU: 1626

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO **Application Number** 10/554,036 October 20, 2005 Filing Date INFORMATION DISCLOSURE First Named Inventor Besidski STATEMENT BY APPLICANT Art Unit Unknown (Use as many sheets as necessary) **Examiner Name** Unknown 101023-1P US Attorney Docket Number

C	Cita	Desument Number	U. S. PATENT DO	Name of Patentee or	Pages, Columns, Lines, Where
Examiner City Initials* No.	Cite No.1	Document Number	MM-DD-YYYY	Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
initiais	NO.	Number-Kind Code ^{2 (# known)}			Figures Appear
		US-			
		US-			· .
	1	US-			
	1	US-			
		US-			
		US-			
		US-			
	1	US-			
	T-	US-			
	-	US-			
	 	US-			·
	+	US-			

		FOREIC	ON PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T6
,		Country Code ^{3 "} Number ^{4 "} Kind Code ⁵ (if known)	MM-DD-YYYY		Of Relevant I igures Appear	
	A10	WO 03/014064	02-20-2003	Bayer Aktiengesellschaft		\vdash
	A11	WO 03/037274	05-08-2003			-
<u> </u>		WO 2004/011440	02-05-2004	Banyu Pharmaceutical Co.		
-		WO 2004/056774	07-08-2004	Neurogen Corporation		\vdash
	1	WO 03/049702	06-19-03	Amgem Inc.		
<u> </u>	 					لــــــــــــــــــــــــــــــــــــــ

Examiner Signature	/Laura L. Stockton/	Date Considered	12/04/2008
Signature			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not "EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). EAAMINER: initial in reference considered, whether or not citation is in conformance with MPEP obs. Draw line through challen in the conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Uspto Patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, USPTO to process) an application. Submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments including gathering, preparing, and submitting the completed application form to the USPTO. on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Receipt date: 03/17/2006

10554036 - GAU: 1626

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTC	·				Complete if Known
Substitu	e for form 1445/F1C	,			Application Number	10/554,036
INFO	ORMATIO	N DIS	CL	OSURE	Filing Date	October 20, 2005
STA	TEMENT	BY A	PP	LICANT	First Named Inventor	Besidski
	44			1	Art Unit	Unknown
	(Use as many s	ineets as n	ecess	ary)	Examiner Name	Unknown
Sheet	4 3	of	2	4	Attorney Docket Number	101023-1P US

	r	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A15	FREY, C. et al., "Iminoisoindolinone metal complexes, method forhigh-molecular-weight materialcontaining such a metal complex," & EP, 23889, 19810211, accessn1981:444733 ABSTRACT ONLY	
-	A16	MILLER, R. et al., "Schistosoma mansoni: salicylanilides cercarial penetration of mice," & Experimental Parasitology, 61(3), ppg. 359-68, 1956, accession no. 1986:472101	
	A17	PORTNAYA, B. et al., "Azomethine dyes. IV. Indoanilineheterocyclic N-substituted 1-hydroxy-2-naphthamides," & Ts. Vses. NauchnIssled. Kinnofotoinst. (No. 40) 106-18, 1960 ABSTRACT ONLY	
	A18	SHINKAI, H. et al., "Preparation of amide derivatives as nociception antagonists," & WO, A1, 9948492, 19990930, pp. 113, accession no. 1999:626041	
	A19	SUZUKI, N. et al., "Preparation of imidazole derivatives as gonadotropinreleasing hormone antagonists," & JP, A2, 2000095767, 20000404, pp. 79, accession no. 132:265201	
	A20	CHEMCATS, Accession No. 2001:53212, 24 April 2003, 3-Pyridinecarboxamide, N-(2-methyl-5-benzothiazolyl), CASRN 302953-34-0	
	A21	WILLITZER, H. et al., "Synthesis and antiviral activity of substituted 5-ureido- and 5-thioureidobenzimidazole derivatives," & Pharmazie, 33(1), 30-8, 1978	
	A22	Caterina, M.J., Schumacher, M.A., et. al., Nature 1997 vol. 389, pgs 816 - 824	
	A23	Tominaga, M., Caterina, M.J., et al., Neuron 1998, vol. 21 pgs 531 - 543	
	A24	Walker, et al., J. Pharmacol Exp Ther. 2003 Jan; 304(1):56-62	

Examiner Signature	/Laura L. Stockton/	Date Considered	12/04/2008
I Signature			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Receipt date: 03/17/2006

Sheet

4

10554036 - GAU: 1626

Unknown

101023-1P US

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons at		nt and Trademark Office; U.S. DEPARTMENT OF COMMERCE on of information unless it contains a valid OMB control number.
ostitute for form 1449/PTO		Complete if Known
postitute for form 1449/PTO	Application Number	10/554,036
NFORMATION DISCLOSURE	Filing Date	October 20, 2005
STATEMENT BY APPLICANT	First Named Inventor	Besidski
	Art Unit	Unknown
(Use as many sheets as necessary)	E Name	

Attorney Docket Number

Examiner Name

Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A25	Rashid, et al, J Pharmacol Exp Ther. 2003 March;304(3):940-948	
	A26	Hwang and Oh Curr Opin Pharmacol 2002 June; 2(3):235-242	
	A27	Yiangou, et al BJU Int 2001 june; 87(9): 774-779, Szallasi Am J Clin Pathol 2002 118: 110-121	
	A28	STN International, Caplus Acces No. 2004:101143, document no. 140:146168, Moriya, Minoru, et al; "Antagonist of Active Ingredient"; & WO, A1, 2004011440, 20040205, 112	
· <u></u>	A29	STN International File Registry, January 2001 July 30, 2004	
	A30	Mark E. McDonnell, et al.; Bioorganic & Medicinal Chemistry Letters 14 (2004); pages 531-534	
<u> </u>			

Examiner Signature	/Laura L. Stockton/	Date Considered	12/04/2008
Olginataro		ALDED COO. Drow line through C	tetion if not in conformance and not

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.